Transcode Therapeutics Inc Financials
This page shows Transcode Therapeutics Inc (RNAZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Transcode Therapeutics Inc's EBITDA was -$15.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.3% from the prior year.
Transcode Therapeutics Inc generated -$13.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 26.2% from the prior year.
Transcode Therapeutics Inc reported -$16.8M in net income in fiscal year 2024. This represents an increase of 9.7% from the prior year.
Transcode Therapeutics Inc earned $-47.14 per diluted share (EPS) in fiscal year 2024. This represents an increase of 98.6% from the prior year.
Transcode Therapeutics Inc held $5.8M in cash against $0 in long-term debt as of fiscal year 2024.
Transcode Therapeutics Inc had 36,753 shares outstanding in fiscal year 2024. This represents an increase of 93.3% from the prior year.
Transcode Therapeutics Inc invested $9.7M in research and development in fiscal year 2024. This represents a decrease of 20.9% from the prior year.
Transcode Therapeutics Inc invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 38.9% from the prior year.
RNAZ Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.2M+23.2% | $2.6M+15.6% | $2.2M | N/A | $1.2M-60.2% | $3.1M+75.2% | $1.8M | N/A |
| SG&A Expenses | $1.4M-15.4% | $1.7M+73.9% | $952K | N/A | $938K-53.8% | $2.0M+32.8% | $1.5M | N/A |
| Operating Income | -$4.6M-8.1% | -$4.2M-33.1% | -$3.2M | N/A | -$2.2M+57.7% | -$5.1M-55.5% | -$3.3M | N/A |
| Interest Expense | $6K | N/A | $114 | N/A | $11K+140.8% | $4K-53.8% | $10K | N/A |
| Income Tax | N/A | N/A | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$4.9M-13.6% | -$4.3M+64.6% | -$12.1M | N/A | -$2.3M+55.3% | -$5.2M-56.0% | -$3.3M | N/A |
| EPS (Diluted) | $-5.82-13.5% | $-5.13-104.4% | $-2.51 | N/A | $-146.06+78.5% | $-680.23-3086.1% | $-21.35 | N/A |
RNAZ Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.2M-36.8% | $8.3M-37.3% | $13.2M+80.9% | $7.3M+85.3% | $3.9M-18.4% | $4.8M-33.8% | $7.3M+41.0% | $5.2M |
| Current Assets | $4.8M-42.4% | $8.2M-36.8% | $13.0M+83.9% | $7.1M+96.4% | $3.6M-17.6% | $4.4M-34.7% | $6.7M+50.7% | $4.5M |
| Cash & Equivalents | $2.8M-61.5% | $7.4M-36.3% | $11.6M+99.1% | $5.8M+209.8% | $1.9M-44.1% | $3.4M-31.7% | $4.9M+77.5% | $2.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+79.4% | $2.1M-27.0% | $2.9M-68.8% | $9.3M+307.8% | $2.3M-34.8% | $3.5M+29.4% | $2.7M-23.3% | $3.5M |
| Current Liabilities | $3.0M+89.6% | $1.6M-37.6% | $2.5M-9.5% | $2.8M+21.4% | $2.3M-34.8% | $3.5M+29.4% | $2.7M-22.5% | $3.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.4M-76.8% | $6.1M-40.3% | $10.3M+609.9% | -$2.0M-222.2% | $1.7M+24.9% | $1.3M-71.2% | $4.6M+179.4% | $1.6M |
| Retained Earnings | -$84.4M-6.1% | -$79.6M-5.7% | -$75.3M-19.1% | -$63.2M-10.4% | -$57.3M-4.2% | -$54.9M-10.4% | -$49.7M-7.2% | -$46.4M |
RNAZ Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$3.1M | N/A | N/A | N/A | -$3.9M | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $4K | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$3.9M | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$4K | N/A |
| Financing Cash Flow | N/A | N/A | $8.9M | N/A | N/A | N/A | $6.1M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNAZ Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -92.9%-41.2pp | -51.7%+39.9pp | -91.6% | N/A | -59.0%+48.6pp | -107.6%-62.0pp | -45.6% | N/A |
| Current Ratio | 1.60-3.7 | 5.27+0.1 | 5.20+2.6 | 2.56+1.0 | 1.58+0.3 | 1.25-1.2 | 2.48+1.2 | 1.28 |
| Debt-to-Equity | 2.67+2.3 | 0.34+0.1 | 0.28+4.9 | -4.61-6.0 | 1.38-1.3 | 2.65+2.1 | 0.59-1.6 | 2.15 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$2.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Financial Health Signals
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Operating income vs interest expense. Above 5x = safe, below 2x = risky.
Similar Companies
Frequently Asked Questions
Is Transcode Therapeutics Inc profitable?
No, Transcode Therapeutics Inc (RNAZ) reported a net income of -$16.8M in fiscal year 2024.
What is Transcode Therapeutics Inc's earnings per share (EPS)?
Transcode Therapeutics Inc (RNAZ) reported diluted earnings per share of $-47.14 for fiscal year 2024. This represents a 98.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Transcode Therapeutics Inc's EBITDA?
Transcode Therapeutics Inc (RNAZ) had EBITDA of -$15.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Transcode Therapeutics Inc's free cash flow?
Transcode Therapeutics Inc (RNAZ) generated -$13.4M in free cash flow during fiscal year 2024. This represents a 26.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Transcode Therapeutics Inc's operating cash flow?
Transcode Therapeutics Inc (RNAZ) generated -$13.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Transcode Therapeutics Inc's total assets?
Transcode Therapeutics Inc (RNAZ) had $7.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Transcode Therapeutics Inc's capital expenditures?
Transcode Therapeutics Inc (RNAZ) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Transcode Therapeutics Inc spend on research and development?
Transcode Therapeutics Inc (RNAZ) invested $9.7M in research and development during fiscal year 2024.
How many shares does Transcode Therapeutics Inc have outstanding?
Transcode Therapeutics Inc (RNAZ) had 36,753 shares outstanding as of fiscal year 2024.
What is Transcode Therapeutics Inc's current ratio?
Transcode Therapeutics Inc (RNAZ) had a current ratio of 2.56 as of fiscal year 2024, which is generally considered healthy.
What is Transcode Therapeutics Inc's debt-to-equity ratio?
Transcode Therapeutics Inc (RNAZ) had a debt-to-equity ratio of -4.61 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Transcode Therapeutics Inc's return on assets (ROA)?
Transcode Therapeutics Inc (RNAZ) had a return on assets of -229.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Transcode Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Transcode Therapeutics Inc (RNAZ) had $5.8M in cash against an annual operating cash burn of $13.3M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Transcode Therapeutics Inc's debt-to-equity ratio negative or unusual?
Transcode Therapeutics Inc (RNAZ) has negative shareholder equity of -$2.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Transcode Therapeutics Inc's Piotroski F-Score?
Transcode Therapeutics Inc (RNAZ) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Transcode Therapeutics Inc's earnings high quality?
Transcode Therapeutics Inc (RNAZ) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.
Can Transcode Therapeutics Inc cover its interest payments?
Transcode Therapeutics Inc (RNAZ) has an interest coverage ratio of -584.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.